A prospective 8 week trial of nasal interfaces vs. a novel oral interface (Oracle™) for treatment of obstructive sleep apnea hypopnea syndrome A prospective 8 week trial of nasal interfaces vs. a novel oral interface (Oracle™) for treatment of obstructive sleep apnea hypopnea syndrome Download Journal search and commentary – Volume 4 Issue 3 V4I5-Management of restless legs syndrome by the partial D2-agonist terguride